Altre lingue Pacira BioSciences, Inc.

Azioni

PCRX

US6951271005

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:00 06/05/2024			Variaz. 5gg	Var. 1 gen.
26,5 ^USD	-2,61%		+1,73%	-21,46%

13/03	Transcript : Pacira BioSciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM
13/03	Pacira BioSciences afferma che la FDA statunitense ha concesso al candidato terapeutico per l'osteoartrite del ginocchio la designazione RMAT	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	14:01
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024	30/04
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference	02/04
Los bancos occidentales advierten de los riesgos del plan de la UE para usar los activos rusos	22/03
Beyond the Pill: Athletes Champion PEMF and Non-Opioid Solutions for Pain Management (ENDV)	20/03
Pacira BioSciences Says US FDA Granted Knee Osteoarthritis Therapy Candidate RMAT Designation	13/03
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy Designation for the Treatment of Osteoarthritis of the Knee	13/03
Pacira Biosciences Insider Sold Shares Worth $3,656,226, According to a Recent SEC Filing	08/03
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference	06/03
Pacira BioSciences' Shares Rise After Company Posts Higher Q4 Non-GAAP Net Income, Revenue	29/02
Pacira: Q4 Earnings Snapshot	29/02
Pacira BioSciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	29/02
Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024	29/02
Pacira BioSciences, Inc. Provides Earnings Guidance for the Year 2024	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Reports Q4 Revenue $181.2M, vs. Street Est of $180.9M	29/02
Earnings Flash (PCRX) PACIRA BIOSCIENCES Posts Q4 EPS $0.89, vs. Street Est of $0.85	29/02
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results	29/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pacira BioSciences, Inc.

Azioni

PCRX

US6951271005

Altre lingue

Filtri